Beyond the Burden: Elevating Immunotherapy in Colorectal Cancer
Colorectal cancers treated with targeted therapies frequently acquire numerous subclonal genomic alterations. Tumor mutational burden (TMB) is under investigation as a biomarker for predicting response to immunotherapy in microsatellite-stable metastatic colorectal cancer. In this study, we contextualize a recent study evaluating high plasma TMB after targeted therapy and its implications for immunotherapy. See related article by Yeh et al., p. 1100.
Authors
- Christine Megerdichian Parseghian (ORCID: https://orcid.org/0000-0002-2047-097X)
- Madhulika Eluri (ORCID: https://orcid.org/0000-0003-1424-6370)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-4251
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00